Arcus Biosciences Inc (RCUS) COM USD0.0001

Sell:$13.07Buy:$13.10$0.40 (3.15%)

Prices delayed by at least 15 minutes
Sell:$13.07
Buy:$13.10
Change:$0.40 (3.15%)
Prices delayed by at least 15 minutes
Sell:$13.07
Buy:$13.10
Change:$0.40 (3.15%)
Prices delayed by at least 15 minutes

Company Information

About this company

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Key people

Terry J. Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Juan Carlos Jaen
President, Co-Founder
Robert C. Goeltz
Chief Financial Officer
Jennifer A. Jarrett
Chief Operating Officer
Carolyn Tang
General Counsel
Richard Markus
Chief Medical Officer
Yasunori Kaneko
Lead Independent Director
Dietmar P. Berger
Director
Linda Higgins
Director
Johanna Mercier
Director
Kathryn E. Falberg
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US03969F1093
  • Market cap
    $1.10bn
  • Employees
    577
  • Shares in issue
    91.51m
  • Exchange
    New York Stock Exchange
  • Index
    S&P 600 Small Cap, TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.